Bristol Myers Squibb

Bristol Myers Squibb (BMS) is a global biopharmaceutical company headquartered in Princeton, New Jersey. BMS develops and commercializes medicines in oncology, hematology, immunology, and cardiovascular therapy. The company's portfolio includes internally discovered assets and products added through acquisitions documented in SEC filings.

Immuno-oncology is central to BMS, including nivolumab (Opdivo) and ipilimumab (Yervoy), with indications listed in FDA databases. Hematology includes multiple myeloma assets such as Revlimid and Pomalyst, subject to patent and generic entry timelines disclosed in SEC reports. Cardiovascular includes Eliquis (apixaban), co-developed and co-commercialized with Pfizer per public labeling.

• FDA records document Opdivo label expansions across solid tumors and adjuvant settings.
• SEC filings discuss the post-Celgene integration and hematology portfolio lifecycle.
• ClinicalTrials.gov lists BMS-sponsored combination studies in melanoma, lung cancer, and hematologic malignancies.
• Investor materials address patent cliff mitigation strategies without relying on unaudited forecasts here.

BMS pipeline and deal activity appear in 10-K pipeline tables, FDA approval databases, and ClinicalTrials.gov. Recent strategic actions include acquisitions and divestitures disclosed through SEC 8-K filings. Readers should verify current development status directly from those sources.